Cabozantinib regulatory update

In December, Exelixis began submission of a rolling NDA to FDA for cabozantinib for medullary thyroid cancer (MTC). The company plans to complete the submission this half. The spectrum-selective kinase inhibitor of VEGF receptor 2 ( KDR/Flk-1) and c-Met receptor tyrosine kinase has Orphan Drug designation in the U.S. to treat follicular, medullary and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. ...